Media coverage about iRadimed Corporation (NASDAQ:IRMD) has trended somewhat positive on Tuesday, Accern Sentiment reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. iRadimed Corporation earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 45.3440718354031 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Several equities analysts have weighed in on the company. TheStreet upgraded iRadimed Corporation from a “d” rating to a “c-” rating in a report on Friday, June 23rd. Zacks Investment Research upgraded iRadimed Corporation from a “sell” rating to a “hold” rating in a report on Thursday, June 29th. ValuEngine cut iRadimed Corporation from a “hold” rating to a “sell” rating in a report on Saturday, June 24th. Finally, Roth Capital upgraded iRadimed Corporation from a “neutral” rating to a “buy” rating and raised their price target for the company from $9.00 to $12.00 in a report on Monday, July 31st.

iRadimed Corporation (IRMD) traded down 1.01% during trading on Tuesday, reaching $9.85. The company’s stock had a trading volume of 1,134 shares. The stock has a 50-day moving average of $9.94 and a 200 day moving average of $8.89. The firm has a market capitalization of $104.23 million, a P/E ratio of 41.21 and a beta of 1.50. iRadimed Corporation has a one year low of $7.85 and a one year high of $18.00.

iRadimed Corporation (NASDAQ:IRMD) last released its quarterly earnings results on Friday, July 28th. The medical equipment provider reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.07. iRadimed Corporation had a return on equity of 8.98% and a net margin of 11.61%. The company had revenue of $5.50 million during the quarter, compared to analysts’ expectations of $5.41 million. During the same quarter in the prior year, the firm posted $0.24 EPS. iRadimed Corporation’s quarterly revenue was down 44.4% compared to the same quarter last year. On average, equities research analysts predict that iRadimed Corporation will post $0.13 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “iRadimed Corporation (IRMD) Given Daily News Sentiment Score of 0.15” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/19/iradimed-corporation-irmd-given-daily-news-sentiment-score-of-0-15.html.

iRadimed Corporation Company Profile

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.

Insider Buying and Selling by Quarter for iRadimed Corporation (NASDAQ:IRMD)

Receive News & Stock Ratings for iRadimed Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed Corporation and related stocks with our FREE daily email newsletter.